Challenges in the management of recurrent endometrial cancer  by Wang, Peng-Hui et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 79 (2016) 171e173
www.jcma-online.comEditorialhttp://d
1726-4
licenseChallenges in the management of recurrent endometrial cancerIt is generally believed that the outcomes of women with
endometrial cancer are better than those used to be.1 Based on
the fact that most patients with endometrial cancer have their
disease detected and managed in the early stage, and
pathologic cell types were less invasive (e.g., Grades 1 and 2,
as well as Type Idendometrioid cell type),2,3 the majority of
patients with a diagnosis of endometrial cancer can be
successfully managed by standard staging surgeries, including
cytology, total hysterectomy, bilateral salpingo-oophorectomy,
bilateral pelvic lymph node dissection, and para-aortic lymph
node dissection; most patients can be cured and/or controlled
adequately.4,5 In addition, some patients with, for example,
younger age, and International Federation of Gynecology and
Obstetrics (FIGO) Stage IA, Grade 1, endometrioid-type
carcinoma can be treated with more conservative therapy,
including fertility preservation and/or ovary preservation.6
However, recurrence- and disease-related death will occur in
a certain percentage of patients with endometrial cancer after
primary treatment. Therefore, some risk factors have been
reported; for patients having these risk factors, various kinds
of postoperative adjuvant therapies, including chemotherapy
(CT), radiation therapy (RT), tumor excision, and others not
specified, have been suggested. All efforts are applied to
minimize the risk of recurrence and therapeutic failure,
because it is very difficult to medically manage women with
recurrent endometrial cancer.
Although many strategies can be applied for women with
recurrent endometrial cancers, the resulting therapeutic effects
are uncertain. Conventionally, recurrent tumors can briefly be
separated into local recurrence and distant metastasis, or can
be synchronous at both sites. By definition, local recurrence is
limited to pelvic recurrence, especially recurrence on the
vaginal cuff. Management of local recurrence may be much
easier, although greatly varied, because these patients can
undergo tumor excision, RT, CT, or a combination of any of
these. By contrast, distant metastasis is occurrence of the
tumor outside of the pelvic cavity and is often considered a
systemic disease. In theory, it is nearly impossible to totally
eradicate the tumors without a systemic therapy strategy.
Under these circumstances, only CT and/or hormone therapy
can achieve this goal; however, endometrial cancer is rela-
tively resistant to CT and often unresponsive to hormonex.doi.org/10.1016/j.jcma.2015.11.005
901/Copyright © 2015, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).therapy. Therefore, CT and hormone therapy are frequently
viewed as palliative treatments. Ultimately, this suggests that
there is no reasonable rationale to consider the use of surgery
and/or definite RT in the management of these patients with
distant metastases. However, this aversion to surgical/RT
intervention might not be applicable for several organs (e.g.,
the lung or spleen), because these types of metastases might be
successfully and totally eradicated by surgery and/or definite
RT. Bogani et al7 commented that both exenterative and
nonexenterative surgical procedures play an important role in
locoregional control, thus improving both progression-free and
overall survival rates, especially in those patients suffering
later recurrences (selected cases).
The study by Turan et al8 in this issue of the Journal of the
Chinese Medical Association (JCMA), entitled “Pulmonary
recurrence in patients with endometrial cancer” addressed one
of the abovementioned situationsdpulmonary recurrence of
patients with endometrial cancer after primary treatment.
There is no doubt that, by definition, pulmonary recurrence is
a pattern of distant metastases and systemic disease, and the
study hinted that surgery and/or RT might not be the first
choice for these patients. Turan et al8 found that surgery
(pulmonary metastasectomy) may not improve overall sur-
vival, even though some patients had complete tumor resection
without any residual tumor, and their prognosis seemed not to
be better; therefore, they suggested that systemic treatment for
pulmonary recurrence might provide better survival. A similar
finding was previously reported by Dowdy et al,9 who found
that thoracotomy was not associated with a survival advantage.
However, we should read their articles in detail and digest
them carefully. Turan et al8 enrolled 36 women with pulmo-
nary recurrence in their study. Only 11% of the study patients
were surgically treated (pulmonary metastasectomy) and the
absolute number of patients was only four. The significant and
extremely smaller sample size might contribute to the
abovementioned conclusion. Dowdy et al9 even found that
treatment with CT was associated with poor outcomes. By
contrast, many studies supported the potential benefits of
pulmonary metastasectomy in highly selected patients with
pulmonary recurrence of endometrial cancer.7,10,11 For
example, Paik et al10 found that, in their study, the 5-year
survival rate after pulmonary metastasectomy was 48.2%.sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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and showed a 10-year survival rate of 34.3% in patients
undergoing pulmonary metastasectomy for the recurrence of
gynecologic cancers, although the overall 3-year disease-free
survival rate was only 27.8%.
As early as 1996, Bouros and colleagues12 attempted to
investigate the natural history of patients with pulmonary
metastases from uterine cancer, and found that the mean
interval time between the diagnosis of uterine cancer and
pulmonary metastases was 29.4 months (range: 0e25 years).
In addition, they found that patients with isolated pulmonary
metastasis had prolonged survival (36 months), irrespective of
whether they were treated medically or surgically.12 However,
although more than 20 years have passed., a similar
resultdrecurrence limited to the lung may lead to better
survival than synchronous recurrence at pulmonary and
extrapulmonary sites, as reported in Turan et al's8 study in the
current JCMA issuedsuggests that there is no significant
improvement in therapy for these advanced and/or recurrent
endometrial cancers that are either limited to the lung or
widespread to other organs. Physicians attempted to identify
any clinicopathological factors following initial surgical
treatment, to predict the risk of therapeutic failure and recur-
rence. For example, the authors described that FIGO stage was
an independent factor for predicting pulmonary recurrence in
women with endometrial cancer after initial treatment.
However, due to the absence of an agreement in choices of
adjuvant therapy,13 it is still uncertain which protocols
provided benefits for these high-risk patients. In our opinion,
in the absence of clear evidence suggesting a more effective
adjuvant therapy for the prevention of recurrences and/or
metastases, along with a more efficient rescue therapy for
these patients when they had recurrences and/or metastases,
clinicians have a long path to travel before they can medically
manage women with advanced and/or recurrent endometrial
cancer with confidence and success. Fortunately, many of the
largest-series studies, either retrospectively or prospectively,
have focused on this challenging disease, and some of them
might prove to be relatively promising.14
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